FDA Approves Merck's JUVISYNC (Sitagliptin And Simvastatin) - Pharmaceutical Online (press release) Print
Pharmaceutical Online (press release)
Because doses of JUVISYNC appropriate for patients with moderate or severe renal impairment (CrCl <50 mL/min, approximately corresponding to serum creatinine levels of >1.7 mg/dL in men and >1.5 mg/dL in women) or end-stage renal disease (ESRD) are not

...